Caicun Zhou - Concepedia

Author

Caicun Zhou

Also Known As

C Zhou, C. Zhou, C.-C. Zhou, CAICUN ZHOU, Cai-Cun Zhou, Cai-cun ZHOU, Cai-cun Zhou, Caicun Zhou, Cai‐Cun Zhou, Chengkang Zhou

226

Publications

7.7K

Citations

H-Index

Concepts

All Affiliations

Shanghai Pulmonary Hospital Tongji University Hunan Cancer Hospital Peking University Peking University Cancer Hospital

About

Caicun Zhou is an author at Shanghai Pulmonary Hospital specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	43	4.2K
2	Health Sciences	12	12	1.1K
3	Cell Biology	12	12	695
4	Immunology	12	12	620
5	Engineering	1	1	20

Caicun Zhou

Publications

6.9K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, The Lancet OncologyAdjuvant ChemotherapyPathologyImmune Checkpoint InhibitorCancer Treatment	2021	1.4K
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial Caicun Zhou, Gongyan Chen, Yunchao Huang, The Lancet Respiratory Medicine OncologyClinical TrialsChemotherapy-naive PatientsImmune Checkpoint InhibitorPharmacotherapy	2020	488
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy Tony Mok, Yi‐Long Wu, Jin Soo Lee, Clinical Cancer Research	2015	468
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial Shengxiang Ren, Jianhua Chen, Xingxiang Xu, Journal of Thoracic Oncology Camrelizumab Plus CarboplatinMedicineAdvanced Squamous NsclcPharmacologyClinical Trials	2021	293
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim, JAMA Oncology	2021	282
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, Annals of Oncology	2023	230
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib Y. Wang, Tao Jiang, Zhen Qin, Annals of Oncology	2018	209
Early detection of lung cancer by using an autoantibody panel in Chinese population Shengxiang Ren, Shucai Zhang, Tao Jiang, OncoImmunology Epidemiology Of CancerImmunology7-Aabs PanelPathologyOncology	2017	200
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial Jianxing He, Chunxia Su, Wenhua Liang, The Lancet Respiratory Medicine MedicineImmunologyPathologyAdjuvant TreatmentImmune Checkpoint Inhibitor	2021	178
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer Bing Li, Shengxiang Ren, Xuefei Li, Lung Cancer Tumor BiologyOncologyMedicineMir-21 OverexpressionPathology	2013	175

Page 1